CTLT240920P52500
- 0.05
- 0.000.00%
Catalent Newsroom
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Do Options Traders Know Something About Catalent (CTLT) Stock We Don't?
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight
Catalent | 10-K: FY2024 Annual Report
Contract Development & Manufacturing Organization (CDMO) Market Insights & Forecast 2024-2028, Featuring Profiles of Catalent, Recipharm, Evotec, Lonza, Biomerieux and Thermo Fisher Scientific - ResearchAndMarkets.com
Catalent Delays 10-K Filing
Express News | Catalent Inc Says Files Non-Timely 10-K With U.S. SEC
Is Catalent (NYSE:CTLT) A Risky Investment?
Morgan Stanley Fund: Will the pharmaceutical stocks "counterattack" as the Federal Reserve cuts interest rates?
Morgan Stanley Fund said that if the Federal Reserve cuts interest rates, risk appetite for funds may increase, and innovative drugs with higher growth potential may receive more risk capital favor in the short to medium term, gaining some upward momentum.
American Injectables CEO Beau Garrett Comments on the Catalent-Novo Transaction: A Catalyst for Competition and Innovation
Catalent Ends FY24 on a Strong Note Ahead of Novo Buyout
Sector Update: Health Care Stocks Advance Premarket Thursday
Catalent Beats Revenue Estimates Ahead of Deal Close With Novo Nordisk Parent
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Catalent: Novo Transaction Expected to Close Toward End of Calendar 2024 >CTLT
Express News | Catalent Inc- Qtrly Adj EPS $0.65
Express News | Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
Express News | Catalent Q4 Adjusted Net Income USD 118 Million Vs. IBES Estimate USD 84.8 Million